Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 233

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 8
Chunk 233
---

    $1,774,210  
    $612,034  
     34.5%
  
    General and administrative 
     1,976,335  
     2,628,028  
     (651,693) 
     (24.8)%
  
    Total operating expenses 
     4,362,579  
     4,402,238  
     (39,659) 
     (0.9)%
  
    Loss from operations 
     (4,362,579) 
     (4,402,238) 
     39,659  
     (0.9)%

    Other income (expense): 

    Other income (expenses) 
     248  
     (147) 
     395  
     268.7%
  
    Change in fair value of earnout and derivative liabilities 
     —  
     170,000  
     170,000  
     (100.0)%
  
    Write off of deferred offering costs 
     (500,000) 
     -  
     (500,000) 
     (100.0)%
  
    Interest income (expense), net 
     5,936  
     4,418  
     1,518  
     34.4%
  
    Total other income (expense), net 
     (493,816) 
     174,271  
     (668,087) 
     (383.4)%

    Net loss 
     (4,856,395) 
     (4,227,967) 
     (628,428) 
     14.9%
  
    Deemed dividend on Series D Preferred Stock 
     (6,649,828) 
     —  
     (6,649,828) 
     100.0%
  
    Net loss attributable to common stockholders 
    $(11,506,223) 
    $(4,227,967) 
    $(7,278,256) 
     172.1%

Research and Development Expenses

Research and development
expenses were $2,386,000 for the three months ended September 30, 2025 as compared to $1,774,000 for the three months ended September
30, 2024, reflecting an